GTSM:4911

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

G&E Herbal Biotechnology

Executive Summary

G&E Herbal Biotechnology Co., Ltd., a biotechnology company, focuses on the development and commercialization of novel botanical extraction technology and products in Taiwan. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has G&E Herbal Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4911 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4911's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-3.0%

4911

-1.8%

TW Personal Products

-0.1%

TW Market


1 Year Return

-6.8%

4911

12.1%

TW Personal Products

41.5%

TW Market

Return vs Industry: 4911 underperformed the TW Personal Products industry which returned 10.5% over the past year.

Return vs Market: 4911 underperformed the TW Market which returned 40.3% over the past year.


Shareholder returns

4911IndustryMarket
7 Day-3.0%-1.8%-0.1%
30 Day1.3%8.6%5.6%
90 Day-14.0%-0.4%15.0%
1 Year-6.8%-6.8%16.7%12.1%46.5%41.5%
3 Year-36.7%-36.7%13.5%5.1%67.1%48.2%
5 Year-63.2%-63.2%20.1%4.4%123.0%83.7%

Long-Term Price Volatility Vs. Market

How volatile is G&E Herbal Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is G&E Herbal Biotechnology undervalued compared to its fair value and its price relative to the market?

2.42x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4911's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4911's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4911 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.

PE vs Market: 4911 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4911's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4911's PB Ratio (2.4x) is in line with the TW Personal Products industry average.


Next Steps

Future Growth

How is G&E Herbal Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.7%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as G&E Herbal Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has G&E Herbal Biotechnology performed over the past 5 years?

-11.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4911 is currently unprofitable.

Growing Profit Margin: 4911 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4911 is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.

Accelerating Growth: Unable to compare 4911's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4911 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (-14.9%).


Return on Equity

High ROE: 4911 has a negative Return on Equity (-2.21%), as it is currently unprofitable.


Next Steps

Financial Health

How is G&E Herbal Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: 4911's short term assets (NT$145.1M) exceed its short term liabilities (NT$7.9M).

Long Term Liabilities: 4911 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 4911 is debt free.

Reducing Debt: 4911 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4911 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4911 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 31.7% each year


Next Steps

Dividend

What is G&E Herbal Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4911's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4911's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4911's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4911's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 4911 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4911's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

G&E Herbal Biotechnology has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

G&E Herbal Biotechnology Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: G&E Herbal Biotechnology Co., Ltd.
  • Ticker: 4911
  • Exchange: GTSM
  • Founded: 2002
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$1.753b
  • Shares outstanding: 55.66m
  • Website: https://www.geherbs.com.tw

Number of Employees


Location

  • G&E Herbal Biotechnology Co., Ltd.
  • No.92, Keji 5th Road
  • Annan District
  • Tainan City
  • 70955
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4911GTSM (Taipei Exchange)YesCommon StockTWTWDApr 2008

Biography

G&E Herbal Biotechnology Co., Ltd., a biotechnology company, focuses on the development and commercialization of novel botanical extraction technology and products in Taiwan. It offers hepato protective ag...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/03 08:34
End of Day Share Price2021/03/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.